Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.16 (market cap $39.89B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $28.31. The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FNGU | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $36.15 |
52-Week Low | $278.09 | $13.73 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FNGU trades at $28.64, up 0.77% on the day, with technical indicators showing a bullish trend from moving averages but caution from oscillators like the 6-day RSI at 95.66. Recent news highlights extreme volatility, with a 16% single-session drop reported on June 5, 2026, underscoring the leveraged ETN's high-risk nature. The asset lacks traditional fundamental metrics like P/E or revenue data, as it is an exchange-traded note tracking the FANG+ Index with 3x leverage.
The outlook for FNGU is highly speculative, driven by momentum in tech stocks but fraught with decay risks from daily rebalancing. Opportunities exist for short-term traders betting on Nasdaq-100 rallies, while risks include rapid capital erosion during market downturns, as evidenced by recent losses. Investors must understand the product's structure to avoid unintended losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
